Evolution of Missing Colorectal Liver Metastases Following Inductive Chemotherapy and Hepatectomy

Journal of Surgical Oncology

Volumn 86, Issue 1, 2004, Pages 4-9

  Elias, Dominique ^a   Youssef, Omar ^a   Sideris, Lucas ^a   Dromain, Clarisse ^a   Baton, Olivier ^a   Boige, Valérie ^a   Ducreux, Michel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Colorectal cancer; Complete response; Hepatectomy; Liver metastases; Missing metastasis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG RESPONSE; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; LAPAROTOMY; LIVER METASTASIS; LIVER RESECTION; MALE; MISSING METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 1842852119     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20039     Document Type: Article

References (12)

1. Hobday TJ, Cha SS, Sargent DJ, et al.: Long term survivors (LTS) of metastatic colorectal cancer (MCRC) treated with chemotherapy only: A North Central Cancer Treatment Group (NCCTG) review. Proc of ASCO 2002;693:174a (Abstract).
2. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomized trial. Lancet 2000;355:1041-1047.
3. Goldberg RM, Morton RF, Sargent DJ, et al.: N9741: Oxaliplatin (oxal) or CPT-11+5-fluorouracil (5-FU)/leucovorin (LV) or oxal+CPT-11 in advanced colorectal cancer. Initial toxicity and response data from a GI Intergroup study. Proc of ASCO 2002;21:128a (Abstract).
4. Boige V, Lacombe T, De Baere T, et al.: Hepatic arterial infusion oxaliplatin combined with intravenous 5-FU and folinic acid in non resectable liver metastasis of colorectal origin: a promising option for failures to systemic chemotherapy. Proc Am Soc Clin Oncol 2003;1170a.
5. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Analysis of 1001 consecutive cases. Ann Surg 1999;230:309-321.
6. Elias D, Cavalcanti A, Sabourin JC, et al.: Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 1998;69:88-93.
7. Kokudo N, Miki Y, Sugai S, et al.: Genetic and histological assessment of surgical margins in resected liver metastases from colorectal cancer. Arch Surg 2002;137:833-840.
8. Jarnagin WR, Gonen M, Fong Y, et al.: Improvement in perioperative outcome after hepatic resection. Ann Surg 2002;236:397-407.
9. Elias D, de Baere T, Muttillo I, et al.: Intra-operative use of radiofrequency allows an increase in the rate of curative liver resection. J Surg Oncol 1998;67:190-191.
10. Parikh AA, Curley SA, Fornage BD, et al.: Radiofrequency ablation of hepatic metastases. Seminars Oncol 2002;29:168-182.
11. McCarter MD, Fong Y. Role of surgical cytoreduction in multimodality treatments for cancer. Ann Surg Oncol 2001;8:38-43.
12. Nordlinger B, Rougier P. Liver metastases from colorectal cancer: The turning point. J Clin Oncol 2002;20:1442-1445.